

Urological Cancer Therapeutics Drugs-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/U7BB1D4F265MEN.html>

Date: April 2018

Pages: 160

Price: US\$ 3,480.00 (Single User License)

ID: U7BB1D4F265MEN

Abstracts

Report Summary

Urological Cancer Therapeutics Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Urological Cancer Therapeutics Drugs industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Urological Cancer Therapeutics Drugs 2013-2017, and development forecast 2018-2023

Main market players of Urological Cancer Therapeutics Drugs in Europe, with company and product introduction, position in the Urological Cancer Therapeutics Drugs market
Market status and development trend of Urological Cancer Therapeutics Drugs by types and applications

Cost and profit status of Urological Cancer Therapeutics Drugs, and marketing status
Market growth drivers and challenges

The report segments the Europe Urological Cancer Therapeutics Drugs market as:

Europe Urological Cancer Therapeutics Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Urological Cancer Therapeutics Drugs Market: Product Type Segment Analysis
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Xofigo (radium Ra 223 dichloride)

Jevtana (cabazitaxel)

Inlyta (axitinib)

Votrient (pazopanib hydrochloride)

Sutent (sunitinib malate)

Zytiga (abiraterone acetate)

Xtandi (enzalutamide)

Opdivo (nivolumab)

Provenge (sipuleucel-T)

Europe Urological Cancer Therapeutics Drugs Market: Application Segment Analysis
(Consumption Volume and Market Share 2013-2023; Downstream Customers and
Market Analysis)

Hospital

Medical Research Laboratory

Others

Europe Urological Cancer Therapeutics Drugs Market: Players Segment Analysis
(Company and Product introduction, Urological Cancer Therapeutics Drugs Sales
Volume, Revenue, Price and Gross Margin):

Novartis

Pfizer

Johnson & Johnson

AstraZeneca

Astellas

Bristol-Myers Squibb

Abbott Laboratories

Celgene Corporation

Dendreon Corporation

Ferring Pharmaceuticals

GlaxoSmithKline plc

Indevus Pharmaceuticals Inc

Ipsen
Roche Healthcare
Sanofi S.A.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF UROLOGICAL CANCER THERAPEUTICS DRUGS

- 1.1 Definition of Urological Cancer Therapeutics Drugs in This Report
- 1.2 Commercial Types of Urological Cancer Therapeutics Drugs
 - 1.2.1 Xofigo (radium Ra 223 dichloride)
 - 1.2.2 Jevtana (cabazitaxel)
 - 1.2.3 Inlyta (axitinib)
 - 1.2.4 Votrient (pazopanib hydrochloride)
 - 1.2.5 Sutent (sunitinib malate)
 - 1.2.6 Zytiga (abiraterone acetate)
 - 1.2.7 Xtandi (enzalutamide)
 - 1.2.8 Opdivo (nivolumab)
 - 1.2.9 Provenge (sipuleucel-T)
- 1.3 Downstream Application of Urological Cancer Therapeutics Drugs
 - 1.3.1 Hospital
 - 1.3.2 Medical Research Laboratory
 - 1.3.3 Others
- 1.4 Development History of Urological Cancer Therapeutics Drugs
- 1.5 Market Status and Trend of Urological Cancer Therapeutics Drugs 2013-2023
 - 1.5.1 Europe Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Urological Cancer Therapeutics Drugs Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Urological Cancer Therapeutics Drugs in Europe 2013-2017
- 2.2 Consumption Market of Urological Cancer Therapeutics Drugs in Europe by Regions
 - 2.2.1 Consumption Volume of Urological Cancer Therapeutics Drugs in Europe by Regions
 - 2.2.2 Revenue of Urological Cancer Therapeutics Drugs in Europe by Regions
- 2.3 Market Analysis of Urological Cancer Therapeutics Drugs in Europe by Regions
 - 2.3.1 Market Analysis of Urological Cancer Therapeutics Drugs in Germany 2013-2017
 - 2.3.2 Market Analysis of Urological Cancer Therapeutics Drugs in United Kingdom 2013-2017
 - 2.3.3 Market Analysis of Urological Cancer Therapeutics Drugs in France 2013-2017

- 2.3.4 Market Analysis of Urological Cancer Therapeutics Drugs in Italy 2013-2017
- 2.3.5 Market Analysis of Urological Cancer Therapeutics Drugs in Spain 2013-2017
- 2.3.6 Market Analysis of Urological Cancer Therapeutics Drugs in Benelux 2013-2017
- 2.3.7 Market Analysis of Urological Cancer Therapeutics Drugs in Russia 2013-2017
- 2.4 Market Development Forecast of Urological Cancer Therapeutics Drugs in Europe 2018-2023
 - 2.4.1 Market Development Forecast of Urological Cancer Therapeutics Drugs in Europe 2018-2023
 - 2.4.2 Market Development Forecast of Urological Cancer Therapeutics Drugs by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole Europe Market Status by Types
 - 3.1.1 Consumption Volume of Urological Cancer Therapeutics Drugs in Europe by Types
 - 3.1.2 Revenue of Urological Cancer Therapeutics Drugs in Europe by Types
- 3.2 Europe Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Germany
 - 3.2.2 Market Status by Types in United Kingdom
 - 3.2.3 Market Status by Types in France
 - 3.2.4 Market Status by Types in Italy
 - 3.2.5 Market Status by Types in Spain
 - 3.2.6 Market Status by Types in Benelux
 - 3.2.7 Market Status by Types in Russia
- 3.3 Market Forecast of Urological Cancer Therapeutics Drugs in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Urological Cancer Therapeutics Drugs in Europe by Downstream Industry
- 4.2 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in Germany
 - 4.2.2 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in United Kingdom
 - 4.2.3 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream

Industry in France

4.2.4 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream

Industry in Italy

4.2.5 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream

Industry in Spain

4.2.6 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream Industry in Benelux

4.2.7 Demand Volume of Urological Cancer Therapeutics Drugs by Downstream

Industry in Russia

4.3 Market Forecast of Urological Cancer Therapeutics Drugs in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

5.1 Europe Economy Situation and Trend Overview

5.2 Urological Cancer Therapeutics Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 UROLOGICAL CANCER THERAPEUTICS DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

6.1 Sales Volume of Urological Cancer Therapeutics Drugs in Europe by Major Players

6.2 Revenue of Urological Cancer Therapeutics Drugs in Europe by Major Players

6.3 Basic Information of Urological Cancer Therapeutics Drugs by Major Players

6.3.1 Headquarters Location and Established Time of Urological Cancer Therapeutics Drugs Major Players

6.3.2 Employees and Revenue Level of Urological Cancer Therapeutics Drugs Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 UROLOGICAL CANCER THERAPEUTICS DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 Novartis

7.1.1 Company profile

- 7.1.2 Representative Urological Cancer Therapeutics Drugs Product
- 7.1.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Novartis
- 7.2 Pfizer
 - 7.2.1 Company profile
 - 7.2.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.2.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Pfizer
- 7.3 Johnson & Johnson
 - 7.3.1 Company profile
 - 7.3.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.3.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.4 AstraZeneca
 - 7.4.1 Company profile
 - 7.4.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.4.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
- 7.5 Astellas
 - 7.5.1 Company profile
 - 7.5.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.5.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Astellas
- 7.6 Bristol-Myers Squibb
 - 7.6.1 Company profile
 - 7.6.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.6.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
- 7.7 Abbott Laboratories
 - 7.7.1 Company profile
 - 7.7.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.7.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 7.8 Celgene Corporation
 - 7.8.1 Company profile
 - 7.8.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.8.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Celgene Corporation
- 7.9 Dendreon Corporation

- 7.9.1 Company profile
- 7.9.2 Representative Urological Cancer Therapeutics Drugs Product
- 7.9.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Dendreon Corporation
- 7.10 Ferring Pharmaceuticals
 - 7.10.1 Company profile
 - 7.10.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.10.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ferring Pharmaceuticals
- 7.11 GlaxoSmithKline plc
 - 7.11.1 Company profile
 - 7.11.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.11.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
- 7.12 Indevus Pharmaceuticals Inc
 - 7.12.1 Company profile
 - 7.12.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.12.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Indevus Pharmaceuticals Inc
- 7.13 Ipsen
 - 7.13.1 Company profile
 - 7.13.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.13.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Ipsen
- 7.14 Roche Healthcare
 - 7.14.1 Company profile
 - 7.14.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.14.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Roche Healthcare
- 7.15 Sanofi S.A.
 - 7.15.1 Company profile
 - 7.15.2 Representative Urological Cancer Therapeutics Drugs Product
 - 7.15.3 Urological Cancer Therapeutics Drugs Sales, Revenue, Price and Gross Margin of Sanofi S.A.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

8.1 Industry Chain of Urological Cancer Therapeutics Drugs

8.2 Upstream Market and Representative Companies Analysis

8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

9.1 Cost Structure Analysis of Urological Cancer Therapeutics Drugs

9.2 Raw Materials Cost Analysis of Urological Cancer Therapeutics Drugs

9.3 Labor Cost Analysis of Urological Cancer Therapeutics Drugs

9.4 Manufacturing Expenses Analysis of Urological Cancer Therapeutics Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF UROLOGICAL CANCER THERAPEUTICS DRUGS

10.1 Marketing Channel

10.1.1 Direct Marketing

10.1.2 Indirect Marketing

10.1.3 Marketing Channel Development Trend

10.2 Market Positioning

10.2.1 Pricing Strategy

10.2.2 Brand Strategy

10.2.3 Target Client

10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Reference

I would like to order

Product name: Urological Cancer Therapeutics Drugs-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/U7BB1D4F265MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U7BB1D4F265MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

